CM Management’s Iovance Biotherapeutics IOVA Stock Holding History

CM Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Hold	450,000	–	–	1.19%	38
2026 Q1	$1.58M	Buy	450,000 +50,000	+13%	+$160K	1.32%	26
2025 Q4	$1.09M	Sell	400,000 -300,000	-43%	-$694K	0.92%	38
2025 Q3	$1.52M	Hold	700,000	–	–	1.27%	31
2025 Q2	$1.2M	Buy	700,000 +200,000	+40%	+$498K	1.1%	32
2025 Q1	$1.67M	Buy	500,000 +200,000	+67%	+$1.03M	1.67%	27
2024 Q4	$2.22M	Buy	300,000 +50,000	+20%	+$463K	1.98%	21
2024 Q3	$2.35M	Hold	250,000	–	–	1.87%	21
2024 Q2	$2M	Hold	250,000	–	–	1.84%	22
2024 Q1	$3.71M	Hold	250,000	–	–	3.11%	7
2023 Q4	$2.03M	Buy	250,000 +50,000	+25%	+$262K	1.63%	22
2023 Q3	$910K	Buy	+200,000	New	+$1.31M	0.97%	35

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

CM Management's IOVA Position: Q2 2026 in Review

CM Management held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 450,000 shares worth $1.87M. The position accounts for 1.19% of the portfolio, ranked #38.

CM Management first reported a position in IOVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.71M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

CM Management held 450,000 shares of Iovance Biotherapeutics worth $1.87M as of Q2 2026.
CM Management left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up 1.19% of CM Management's portfolio in Q2 2026, its #38 holding.
CM Management first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 12 quarters since.
CM Management's Iovance Biotherapeutics position peaked at $3.71M in Q1 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.